Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma

NCT07692152 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

350

Enrollment

OTHER

Sponsor class

Conditions

Anal Squamous Cell Carcinoma, Limited-stage

Interventions

RADIATION: Intensity-Modulated Radiotherapy (IMRT)
DRUG: Capecitabine
BIOLOGICAL: Sintilimab
DRUG: Mitomycin (MMC)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences